The Safety Profile of COVID-19 Vaccines: A Narrative Review
,
Abstract
t
The ongoing COVID-19 pandemic inflicted a considerable burden on health systems and individuals worldwide. Thus, scientists intended to propose beneficial treatments and vaccines to fight against this virus. However, vaccination remained the only effective way to reduce death and hospitalization due to COVID-19 infection. To date, about five proposed COVID-19 vaccines have been approved as WHO emergency use listings (EUL). Yet, their safety profile needs the following actions to be revealed: (1) more follow-up registry systems and (2) global clinical trials in various countries in a period that they are experiencing a peak. By searching keywords 'COVID-19' and 'vaccination' in PubMed and Scopus databases, we aimed to summarize the current evidence in the literature regarding the safety profile (i.e., local and systemic adverse events) of ten COVID-19 vaccines: (1) Pfizer/BioNTech, (2) Moderna, (3) Sputnik V, (4) Bharat, (5) CanSino, (6) Sinovac, (7) AstraZeneca, (8) Johnson & Johnson, (9) Novavax, and (10) Sinopharm. Moreover, we demonstrated the data on the safety of heterologous schedules of these vaccines alongside further considerations in people with comorbidities and particular circumstances. Most of the COVID-19 vaccine adverse effects possess a mild-to-moderate, self-limiting nature. However, special circumstances such as severe hyper-sensitivity necessitate the use of an alternate COVID-19 vaccine. Vaccination is the only way to exit the global pandemic, and its benefits outweigh its adverse effects. Meanwhile, people should be aware of the signs of the probable rare, severe reactions to the vaccine.
1. Hatmal MM, Al-Hatamleh MAI, Olaimat AN, Hatmal M, Alhaj-Qasem DM, Olaimat TM, et al. Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects. Vaccines (Basel). 2021;9(6).
2. Organization WH. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 2020 [Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
3. Seyed ASA, Karimi A, Shobeiri P, Nowroozi A, Mehraeen E, Afsahi AM, et al. Psychological symptoms of COVID-19 epidemic: a systematic review of current evidence. Psihologija. 2021(00):35-35.
4. Momtazmanesh S, Shobeiri P, Hanaei S, Mahmoud-Elsayed H, Dalvi BRad EM. Cardiovascular disease in COVID-19: a systematic review and meta-analysis of 10,898 patients and proposal of a triage risk stratification tool. The Egyptian Heart Journal. 2020;72(1):1-17.
5. Mehraeen E, SeyedAlinaghi S, Nowroozi A, Dadras O, Alilou S, Shobeiri P, et al. A systematic review of ECG findings in patients with COVID-19. Indian Heart Journal. 2020.
6. Chen M, Yuan Y, Zhou Y, Deng Z, Zhao J, Feng F, et al. Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials. Infectious Diseases of Poverty. 2021;10(1):94.
7. Randolph HEBarreiro LB. Herd Immunity: Understanding COVID-19. Immunity. 2020;52(5):737-41.
8. Institute M. COVID-19 TREATMENT AND VACCINE TRACKER 2021 [Available from: https://covid-19tracker.milkeninstitute.org/#vaccines_intro.
9. Meo SA, Bukhari IA, Akram J, Meo ASKlonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021;25(3):1663-69.
10. Ball P. The lightning-fast quest for COVID vaccines - and what it means for other diseases. Nature. 2021;589(7840):16-18.
11. Troiano GNardi A. Vaccine hesitancy in the era of COVID-19. Public Health. 2021;194:245-51.
12. Islam MS, Kamal A-HM, Kabir A, Southern DL, Khan SH, Hasan SMM, et al. COVID-19 vaccine rumors and conspiracy theories: The need for cognitive inoculation against misinformation to improve vaccine adherence. PloS one. 2021;16(5):e0251605-e05.
13. Prevention CoDCa. Possible Side Effects After Getting a COVID-19 Vaccine 2021 [Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html.
14. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589-93.
15. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine. 2020.
16. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH 1 T cell responses. Nature. 2020;586(7830):594-99.
17. Walsh EE, Frenck Jr RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine. 2020;383(25):2439-50.
18. A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults [Available from: https://clinicaltrials.gov/ct2/show/NCT04380701.
19. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report [Internet]. Infectious Diseases (except HIV/AIDS); 2020 Jul [cited 2020 Oct 14]. Google Scholar.
20. US vaccine adverse event reporting system (VAERS) [Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-01/06-COVID-Shimabukuro.pdf.
21. Selected Adverse Events Reported after COVID-19 Vaccination [Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html.
22. Riad A, Pokorná A, Attia S, Klugarová J, Koščík MKlugar M. Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. Journal of Clinical Medicine. 2021;10(7):1428.
23. Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. New England Journal of Medicine. 2020;383(25):2427-38.
24. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine. 2021;384(5):403-16.
25. COVID CTeam R. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 Vaccine—United States, December 21, 2020–January 10, 2021. Morbidity and Mortality Weekly Report. 2021;70(4):125.
26. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet. 2020;396(10255):887-97.
27. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. 2021;397(10275):671-81.
28. Jarynowski A, Semenov A, Kamiński MBelik V. Mild Adverse Events of Sputnik V Vaccine Extracted from Russian Language Telegram Posts via BERT Deep Learning Model. medRxiv. 2021:2021.06.14.21258875.
29. Pagotto V, Ferloni A, Soriano MM, Díaz M, Golde MB, González MI, et al. ACTIVE SURVEILLANCE OF THE SPUTNIK V VACCINE IN HEALTH WORKERS. medRxiv. 2021:2021.02.03.21251071.
30. Kyriakidis NC, López-Cortés A, González EV, Grimaldos ABPrado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines. 2021;6(1).
31. news B. Coronavirus: India approves vaccines from Bharat Biotech and Oxford/AstraZeneca 2021 [Available from: https://www.bbc.com/news/world-asia-india-55520658.
32. Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021.
33. Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis. 2021;21(5):637-46.
34. Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial. medRxiv. 2021:2021.06.30.21259439.
35. Srivastava RK, Ish PCovid-Vaccination Group S. The initial experience of COVID-19 vaccination from a tertiary care centre of India. Monaldi Arch Chest Dis. 2021.
36. Desai D, Khan AR, Soneja M, Mittal A, Naik S, Kodan P, et al. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study. The Lancet Infectious Diseases. 2022;22(3):349-56.
37. Ahmed TI, Rishi S, Irshad S, Aggarwal J, Happa KMansoor S. Inactivated vaccine Covaxin/BBV152: A systematic review. Front Immunol. 2022;13:863162.
38. Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. The Lancet. 2020;395(10240):1845-54.
39. Su S, Du LJiang S. Learning from the past: development of safe and effective COVID-19 vaccines. Nature Reviews Microbiology. 2021;19(3):211-19.
40. Reuters. CanSino's COVID-19 vaccine candidate approved for military use in China 2020 [Available from: https://www.reuters.com/article/us-health-coronavirus-china-vaccine-idUSKBN2400DZ.
41. Reuters. China approves two more domestic COVID-19 vaccines for public use 2021 [Available from: https://www.reuters.com/article/us-health-coronavirus-china-vaccine-idUSKBN2AP1MW.
42. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. 2020;396(10249):479-88.
43. Halperin SA, Ye L, MacKinnon-Cameron D, Smith B, Cahn PE, Ruiz-Palacios GM, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. The Lancet. 2022;399(10321):237-48.
44. Organization WH. WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations 2021 [Available from: https://www.who.int/news/item/01-06-2021-who-validates-sinovac-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations.
45. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181-92.
46. Palacios RaB, Ana Paula and Albuquerque, Camila Santos Nascimento and Patiño, Elizabeth González and Santos, Joane do Prado and Tilli Reis Pessoa Conde, Mônica and Piorelli, et al. Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study (April 11, 2021). 2021.
47. Zhang MX, Zhang TT, Shi GF, Cheng FM, Zheng YM, Tung TH, et al. Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. Expert Rev Vaccines. 2021:1-8.
48. Özdemir İ H, Özlek B, Özen MB, Gündüz RBayturan Ö. Type 1 Kounis Syndrome Induced by Inactivated SARS-COV-2 Vaccine. J Emerg Med. 2021.
49. Orenay OM, Balta I, Yigit DEksioglu M. Systemic drug-related intertriginous and flexural exanthema like eruption after CoronaVac vaccine. J Eur Acad Dermatol Venereol. 2021.
50. İremli BG, Şendur SNÜnlütürk U. Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post-vaccination ASIA Syndrome. J Clin Endocrinol Metab. 2021.
51. An QJ, Qin DAPei JX. Reactive arthritis after COVID-19 vaccination. Hum Vaccin Immunother. 2021:1-3.
52. Cebeci FKartal İ. Petechial skin rash associated with CoronaVac vaccination: first cutaneous side effect report before phase 3 results. Eur J Hosp Pharm. 2021.
53. Akdaş E, İlter N, Öğüt BErdem Ö. Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report. J Eur Acad Dermatol Venereol. 2021.
54. Agency EM. EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU 2020 [Available from: https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-astrazeneca-authorisation-eu.
55. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021;397(10269):99-111.
56. Frater J, Ewer KJ, Ogbe A, Pace M, Adele S, Adland E, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV. 2021.
57. Barrett JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, Folegatti PM, Gilbride C, et al. Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021;27(6):1113.
58. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-78.
59. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.
60. Rzymski P, Perek BFlisiak R. Thrombotic Thrombocytopenia after COVID-19 Vaccination: In Search of the Underlying Mechanism. Vaccines. 2021;9(6):559.
61. Tølbøll Sørensen AL, Rolland M, Hartmann J, Harboe ZB, Roed C, Jensen T, et al. A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2. Blood Adv. 2021;5(12):2569-74.
62. Umbrello M, Brena N, Vercelli R, Foa RA, Femia M, Rossi U, et al. Successful treatment of acute spleno-porto-mesenteric vein thrombosis after ChAdOx1 nCoV-19 vaccine. A case report. J Crit Care. 2021;65:72-75.
63. Suresh PPetchey W. ChAdOx1 nCOV-19 vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis (CVST). BMJ Case Rep. 2021;14(6).
64. D'Agostino V, Caranci F, Negro A, Piscitelli V, Tuccillo B, Fasano F, et al. A Rare Case of Cerebral Venous Thrombosis and Disseminated Intravascular Coagulation Temporally Associated to the COVID-19 Vaccine Administration. J Pers Med. 2021;11(4).
65. Mehta PR, Apap Mangion S, Benger M, Stanton BR, Czuprynska J, Arya R, et al. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination - A report of two UK cases. Brain Behav Immun. 2021;95:514-17.
66. Al-Mayhani T, Saber S, Stubbs MJ, Losseff NA, Perry RJ, Simister RJ, et al. Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. J Neurol Neurosurg Psychiatry. 2021.
67. Blauenfeldt RA, Kristensen SR, Ernstsen SL, Kristensen CCH, Simonsen CZHvas AM. Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine. J Thromb Haemost. 2021.
68. Jones M, Boisvert A, Landry JPetrasek PF. Limb ischemia and pulmonary artery thrombosis afer the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine: a case of vaccine-induced immune thrombotic thrombocytopenia. Cmaj. 2021.
69. Haakonsen HBNystedt A. Deep vein thrombosis more than two weeks after vaccination against COVID-19. Tidsskr Nor Laegeforen. 2021;141.
70. Perry RJ, Tamborska A, Singh B, Craven B, Marigold R, Arthur-Farraj P, et al. Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. The Lancet. 2021.
71. Rzymski P, Perek BFlisiak R. Thrombotic Thrombocytopenia after COVID-19 Vaccination: In Search of the Underlying Mechanism. Vaccines (Basel). 2021;9(6).
72. Long B, Bridwell RGottlieb M. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines. Am J Emerg Med. 2021;49:58-61.
73. Sachs UJ, Cooper N, Czwalinna A, Müller J, Pötzsch B, Tiede A, et al. PF4-dependent immunoassays in patients with vaccine-induced immune thrombotic thrombocytopenia (VITT): results of an inter-laboratory comparison. Thromb Haemost. 2021.
74. Bourguignon A, Arnold DM, Warkentin TE, Smith JW, Pannu T, Shrum JM, et al. Adjunct Immune Globulin for Vaccine-Induced Thrombotic Thrombocytopenia. N Engl J Med. 2021.
75. Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. Bmj. 2021;372:n699.
76. Dyer O. Covid-19: EMA defends AstraZeneca vaccine as Germany and Canada halt rollouts. Bmj. 2021;373:n883.
77. Dyer O. Covid-19: US will send 60 million AstraZeneca doses abroad as domestic demand falls. Bmj. 2021;373:n1111.
78. Thakur KT, Tamborska A, Wood GK, McNeill E, Roh D, Akpan IJ, et al. Clinical review of cerebral venous thrombosis in the context of COVID-19 vaccinations: Evaluation, management, and scientific questions. J Neurol Sci. 2021;427:117532.
79. Mahase E. Covid-19: UK offers under 40s alternative to AstraZeneca vaccine to boost confidence. Bmj. 2021;373:n1185.
80. Mahase E. AstraZeneca vaccine: Blood clots are "extremely rare" and benefits outweigh risks, regulators conclude. Bmj. 2021;373:n931.
81. Agency EM. AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets 2021 [Available from: https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood.
82. Bae S, Lee YW, Lim SY, Lee JH, Lim JS, Lee S, et al. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea. J Korean Med Sci. 2021;36(17):e115.
83. Jeon M, Kim J, Oh CELee JY. Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System. J Korean Med Sci. 2021;36(17):e114.
84. Kim SH, Wi YM, Yun SY, Ryu JS, Shin JM, Lee EH, et al. Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience. J Korean Med Sci. 2021;36(14):e107.
85. Shin M, Hyun CY, Choi YH, Choi JY, Lee KHCho YS. COVID-19 Vaccination-Associated Lymphadenopathy on FDG PET/CT: Distinctive Features in Adenovirus-Vectored Vaccine. Clin Nucl Med. 2021.
86. Keshavarz P, Yazdanpanah F, Rafiee FMizandari M. Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review. Acad Radiol. 2021.
87. Nawwar AA, Searle J, Singh RLyburn ID. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F]Choline PET/CT-not only an FDG finding. Eur J Nucl Med Mol Imaging. 2021:1-2.
88. Allen CM, Ramsamy S, Tarr AW, Tighe PJ, Irving WL, Tanasescu R, et al. Guillain-Barré syndrome variant occurring after SARS-CoV-2 vaccination. Ann Neurol. 2021.
89. Maramattom BV, Krishnan P, Paul R, Padmanabhan S, Cherukudal Vishnu Nampoothiri S, Syed AA, et al. Guillain-Barré Syndrome following ChAdOx1-S/nCoV-19 Vaccine. Ann Neurol. 2021.
90. Román GC, Gracia F, Torres A, Palacios A, Gracia KHarris D. Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222). Front Immunol. 2021;12:653786.
91. Singh Malhotra H, Gupta P, Prabhu V, Garg RK, Dandu HAgarwal V. COVID-19 vaccination-associated myelitis. Qjm. 2021.
92. Aladdin YShirah B. New-onset refractory status epilepticus following the ChAdOx1 nCoV-19 vaccine. J Neuroimmunol. 2021;357:577629.
93. Kim JE, Lee H, Paik SS, Moon JY, Yoon HJKim SH. Delayed cutaneous reaction to ChAdOx1 nCoV-19 vaccine: Is it an 'AstraZeneca arm'? J Eur Acad Dermatol Venereol. 2021.
94. Azzi L, Toia M, Stevanello N, Maggi FForlani G. An episode of oral mucositis after the first administration of the ChAdOx1 COVID-19 vaccine. Oral Dis. 2021.
95. Soiza RL, Scicluna CThomson EC. Efficacy and safety of COVID-19 vaccines in older people. Age Ageing. 2021;50(2):279-83.
96. Organization WH. The Oxford/AstraZeneca COVID-19 vaccine: what you need to know[Available from: https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know?gclid=CjwKCAjwrPCGBhALEiwAUl9X0468Xr_yrJeCt3HCMBi1DbdoBTtAW_bWhg2OdxFnf9MifaPwkCJt_hoCUPMQAvD_BwE.
97. Hazlewood GS, Pardo Pardo J, Barnabe C, Schieir O, Barber CEH, Bernatsky S, et al. Canadian Rheumatology Association Recommendation for the Use of COVID-19 Vaccination for Patients With Autoimmune Rheumatic Diseases. J Rheumatol. 2021.
98. Allen-Philbey K, Stennett A, Begum T, Johnson AC, Dobson R, Giovannoni G, et al. Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis. Mult Scler Relat Disord. 2021;52:103028.
99. Lospinoso K, Nichols CS, Malachowski SJ, Mochel MCNutan F. A case of severe cutaneous adverse reaction following administration of the Janssen Ad26.COV2.S COVID-19 vaccine. JAAD Case Rep. 2021;13:134-37.
100. Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. 2021;384(19):1824-35.
101. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;384(23):2187-201.
102. Shay DK, Gee J, Su JR, Myers TR, Marquez P, Liu R, et al. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021. MMWR Morb Mortal Wkly Rep. 2021;70(18):680-84.
103. Tanne JH. Covid-19: US authorises Johnson and Johnson vaccine again, ending pause in rollout. Bmj. 2021;373:n1079.
104. Mahase E. Covid-19: Unusual blood clots are "very rare side effect" of Janssen vaccine, says EMA. Bmj. 2021;373:n1046.
105. Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020;383(24):2320-32.
106. Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021;384(20):1899-909.
107. Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine. 2021.
108. Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, et al. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. New England Journal of Medicine. 2021;386(6):531-43.
109. Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39-51.
110. News B. Sinopharm: Chinese Covid vaccine gets WHO emergency approval 2021 [Available from: https://www.bbc.com/news/world-asia-china-56967973.
111. Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021;326(1):35-45.
112. Almufty HB, Mohammed SA, Abdullah AMMerza MA. Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes Metab Syndr. 2021;15(5):102207.
113. Abu-Hammad O, Alduraidi H, Abu-Hammad S, Alnazzawi A, Babkair H, Abu-Hammad A, et al. Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines. Vaccines (Basel). 2021;9(6).
114. Jayadevan R, Shenoy RTs A. Survey of symptoms following COVID-19 vaccination in India. medRxiv. 2021:2021.02.08.21251366.
115. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. The Lancet Infectious diseases. 2021;21(7):939-49.
116. Chapin-Bardales J, Gee JMyers T. Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines. Jama. 2021;325(21):2201-02.
117. Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, Turner DL, et al. Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Vaccines (Basel). 2021;9(5).
118. Kunal S, Sakthivel P, Gupta NIsh P. Mix and match COVID-19 vaccines: potential benefit and perspective from India. Postgrad Med J. 2021.
119. Groß R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D, et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity. medRxiv. 2021:2021.05.30.21257971.
120. Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021.
121. Shaw RH, Stuart A, Greenland M, Liu X, Nguyen Van-Tam JSSnape MD. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021;397(10289):2043-46.
122. Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. The Lancet.
123. Hillus D, Schwarz T, Tober-Lau P, Hastor H, Thibeault C, Kasper S, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1-nCoV19 and BNT162b2: a prospective cohort study. medRxiv. 2021:2021.05.19.21257334.
124. Prevention ECfDControl. Threat assessment brief: emergence of SARS-CoV-2 B. 1.617 variants in India and situation in the EU/EEA. 2021.
125. Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of COVID-19 vaccines against the B. 1.617. 2 variant. medRxiv. 2021.
126. Li XN, Huang Y, Wang W, Jing QL, Zhang CH, Qin PZ, et al. Efficacy of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study. Emerg Microbes Infect. 2021:1-32.
127. Nanduri S, Pilishvili T, Derado G, Soe MM, Dollard P, Wu H, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1163-66.
128. Gushchin VA, Dolzhikova IV, Shchetinin AM, Odintsova AS, Siniavin AE, Nikiforova MA, et al. Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants. Vaccines (Basel). 2021;9(7).
129. Berkhout BHerrera-Carrillo E. SARS-CoV-2 Evolution: On the Sudden Appearance of the Omicron Variant. J Virol. 2022;96(7):e0009022.
130. Kumar S, Thambiraja TS, Karuppanan KSubramaniam G. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein. J Med Virol. 2022;94(4):1641-49.
131. Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet. 2022;399(10335):1618-24.
132. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. New England Journal of Medicine. 2022;386(16):1532-46.
133. Higdon MM, Baidya A, Walter KK, Patel MK, Issa H, Espié E, et al. Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant. The Lancet Infectious Diseases. 2022;22(8):1114-16.
134. Soiza RL, Scicluna CThomson EC. Efficacy and safety of COVID-19 vaccines in older people. Age and Ageing. 2021;50(2):279-83.
135. Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, et al. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. N Engl J Med. 2021;384(24):2273-82.
136. Prevention CfDCa. COVID-19 Vaccines While Pregnant or Breastfeeding 2022 [Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html#:~:text=If%20trying%20to%20get%20pregnant,testing%20before%20COVID%2D19%20vaccination.
137. Prevention CfDCa. COVID-19 Vaccine Monitoring Systems for Pregnant People 2022 [Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/monitoring-pregnant-people.html.
138. Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, et al. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut. 2021;70(5):865-75.
139. Khan NMahmud N. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications. Gastroenterology. 2021:S0016-5085(21)03066-3.
140. Xu F, Carlson SA, Wheaton AGGreenlund KJ. COVID-19 Hospitalizations Among U.S. Medicare Beneficiaries With Inflammatory Bowel Disease, April 1 to July 31, 2020. Inflammatory Bowel Diseases. 2021;27(7):1166-69.
141. Prevention CfDCa. Data and Statistics-Inflammatory Bowel Disease (IBD) in the United States 2021 [Available from: https://www.cdc.gov/ibd/data-statistics.htm.
142. Noor MTManoria P. Immune Dysfunction in Cirrhosis. Journal of clinical and translational hepatology. 2017;5(1):50-58.
143. John BV, Deng Y, Scheinberg A, Mahmud N, Taddei TH, Kaplan D, et al. Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis. JAMA Internal Medicine. 2021.
144. diseases aaftsol. COVID-19 Vaccine Recommendations for Patients with Liver Disease 2021 [Available from: https://www.aasld.org/sites/default/files/2021-04/AASLD%20COVID-19%20Vaccine%20Recommendations%20for%20Patients%20with%20Liver%20Disease%20-%20FINAL%20-%20APRIL%202021.pdf.
145. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine. 2020;383(27):2603-15.
146. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The New England journal of medicine. 2021;384(5):403-16.
147. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. 2021;397(10275):671-81.
148. Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial. medRxiv. 2021:2021.06.30.21259439.
149. Zhu F-C, Guan X-H, Li Y-H, Huang J-Y, Jiang T, Hou L-H, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. 2020;396(10249):479-88.
150. Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. New England Journal of Medicine. 2021.
2. Organization WH. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 2020 [Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
3. Seyed ASA, Karimi A, Shobeiri P, Nowroozi A, Mehraeen E, Afsahi AM, et al. Psychological symptoms of COVID-19 epidemic: a systematic review of current evidence. Psihologija. 2021(00):35-35.
4. Momtazmanesh S, Shobeiri P, Hanaei S, Mahmoud-Elsayed H, Dalvi BRad EM. Cardiovascular disease in COVID-19: a systematic review and meta-analysis of 10,898 patients and proposal of a triage risk stratification tool. The Egyptian Heart Journal. 2020;72(1):1-17.
5. Mehraeen E, SeyedAlinaghi S, Nowroozi A, Dadras O, Alilou S, Shobeiri P, et al. A systematic review of ECG findings in patients with COVID-19. Indian Heart Journal. 2020.
6. Chen M, Yuan Y, Zhou Y, Deng Z, Zhao J, Feng F, et al. Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials. Infectious Diseases of Poverty. 2021;10(1):94.
7. Randolph HEBarreiro LB. Herd Immunity: Understanding COVID-19. Immunity. 2020;52(5):737-41.
8. Institute M. COVID-19 TREATMENT AND VACCINE TRACKER 2021 [Available from: https://covid-19tracker.milkeninstitute.org/#vaccines_intro.
9. Meo SA, Bukhari IA, Akram J, Meo ASKlonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021;25(3):1663-69.
10. Ball P. The lightning-fast quest for COVID vaccines - and what it means for other diseases. Nature. 2021;589(7840):16-18.
11. Troiano GNardi A. Vaccine hesitancy in the era of COVID-19. Public Health. 2021;194:245-51.
12. Islam MS, Kamal A-HM, Kabir A, Southern DL, Khan SH, Hasan SMM, et al. COVID-19 vaccine rumors and conspiracy theories: The need for cognitive inoculation against misinformation to improve vaccine adherence. PloS one. 2021;16(5):e0251605-e05.
13. Prevention CoDCa. Possible Side Effects After Getting a COVID-19 Vaccine 2021 [Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html.
14. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589-93.
15. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine. 2020.
16. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH 1 T cell responses. Nature. 2020;586(7830):594-99.
17. Walsh EE, Frenck Jr RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine. 2020;383(25):2439-50.
18. A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults [Available from: https://clinicaltrials.gov/ct2/show/NCT04380701.
19. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report [Internet]. Infectious Diseases (except HIV/AIDS); 2020 Jul [cited 2020 Oct 14]. Google Scholar.
20. US vaccine adverse event reporting system (VAERS) [Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-01/06-COVID-Shimabukuro.pdf.
21. Selected Adverse Events Reported after COVID-19 Vaccination [Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html.
22. Riad A, Pokorná A, Attia S, Klugarová J, Koščík MKlugar M. Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. Journal of Clinical Medicine. 2021;10(7):1428.
23. Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. New England Journal of Medicine. 2020;383(25):2427-38.
24. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine. 2021;384(5):403-16.
25. COVID CTeam R. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 Vaccine—United States, December 21, 2020–January 10, 2021. Morbidity and Mortality Weekly Report. 2021;70(4):125.
26. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet. 2020;396(10255):887-97.
27. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. 2021;397(10275):671-81.
28. Jarynowski A, Semenov A, Kamiński MBelik V. Mild Adverse Events of Sputnik V Vaccine Extracted from Russian Language Telegram Posts via BERT Deep Learning Model. medRxiv. 2021:2021.06.14.21258875.
29. Pagotto V, Ferloni A, Soriano MM, Díaz M, Golde MB, González MI, et al. ACTIVE SURVEILLANCE OF THE SPUTNIK V VACCINE IN HEALTH WORKERS. medRxiv. 2021:2021.02.03.21251071.
30. Kyriakidis NC, López-Cortés A, González EV, Grimaldos ABPrado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines. 2021;6(1).
31. news B. Coronavirus: India approves vaccines from Bharat Biotech and Oxford/AstraZeneca 2021 [Available from: https://www.bbc.com/news/world-asia-india-55520658.
32. Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021.
33. Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis. 2021;21(5):637-46.
34. Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial. medRxiv. 2021:2021.06.30.21259439.
35. Srivastava RK, Ish PCovid-Vaccination Group S. The initial experience of COVID-19 vaccination from a tertiary care centre of India. Monaldi Arch Chest Dis. 2021.
36. Desai D, Khan AR, Soneja M, Mittal A, Naik S, Kodan P, et al. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study. The Lancet Infectious Diseases. 2022;22(3):349-56.
37. Ahmed TI, Rishi S, Irshad S, Aggarwal J, Happa KMansoor S. Inactivated vaccine Covaxin/BBV152: A systematic review. Front Immunol. 2022;13:863162.
38. Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. The Lancet. 2020;395(10240):1845-54.
39. Su S, Du LJiang S. Learning from the past: development of safe and effective COVID-19 vaccines. Nature Reviews Microbiology. 2021;19(3):211-19.
40. Reuters. CanSino's COVID-19 vaccine candidate approved for military use in China 2020 [Available from: https://www.reuters.com/article/us-health-coronavirus-china-vaccine-idUSKBN2400DZ.
41. Reuters. China approves two more domestic COVID-19 vaccines for public use 2021 [Available from: https://www.reuters.com/article/us-health-coronavirus-china-vaccine-idUSKBN2AP1MW.
42. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. 2020;396(10249):479-88.
43. Halperin SA, Ye L, MacKinnon-Cameron D, Smith B, Cahn PE, Ruiz-Palacios GM, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. The Lancet. 2022;399(10321):237-48.
44. Organization WH. WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations 2021 [Available from: https://www.who.int/news/item/01-06-2021-who-validates-sinovac-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations.
45. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181-92.
46. Palacios RaB, Ana Paula and Albuquerque, Camila Santos Nascimento and Patiño, Elizabeth González and Santos, Joane do Prado and Tilli Reis Pessoa Conde, Mônica and Piorelli, et al. Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study (April 11, 2021). 2021.
47. Zhang MX, Zhang TT, Shi GF, Cheng FM, Zheng YM, Tung TH, et al. Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. Expert Rev Vaccines. 2021:1-8.
48. Özdemir İ H, Özlek B, Özen MB, Gündüz RBayturan Ö. Type 1 Kounis Syndrome Induced by Inactivated SARS-COV-2 Vaccine. J Emerg Med. 2021.
49. Orenay OM, Balta I, Yigit DEksioglu M. Systemic drug-related intertriginous and flexural exanthema like eruption after CoronaVac vaccine. J Eur Acad Dermatol Venereol. 2021.
50. İremli BG, Şendur SNÜnlütürk U. Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post-vaccination ASIA Syndrome. J Clin Endocrinol Metab. 2021.
51. An QJ, Qin DAPei JX. Reactive arthritis after COVID-19 vaccination. Hum Vaccin Immunother. 2021:1-3.
52. Cebeci FKartal İ. Petechial skin rash associated with CoronaVac vaccination: first cutaneous side effect report before phase 3 results. Eur J Hosp Pharm. 2021.
53. Akdaş E, İlter N, Öğüt BErdem Ö. Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report. J Eur Acad Dermatol Venereol. 2021.
54. Agency EM. EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU 2020 [Available from: https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-astrazeneca-authorisation-eu.
55. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021;397(10269):99-111.
56. Frater J, Ewer KJ, Ogbe A, Pace M, Adele S, Adland E, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV. 2021.
57. Barrett JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, Folegatti PM, Gilbride C, et al. Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021;27(6):1113.
58. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-78.
59. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.
60. Rzymski P, Perek BFlisiak R. Thrombotic Thrombocytopenia after COVID-19 Vaccination: In Search of the Underlying Mechanism. Vaccines. 2021;9(6):559.
61. Tølbøll Sørensen AL, Rolland M, Hartmann J, Harboe ZB, Roed C, Jensen T, et al. A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2. Blood Adv. 2021;5(12):2569-74.
62. Umbrello M, Brena N, Vercelli R, Foa RA, Femia M, Rossi U, et al. Successful treatment of acute spleno-porto-mesenteric vein thrombosis after ChAdOx1 nCoV-19 vaccine. A case report. J Crit Care. 2021;65:72-75.
63. Suresh PPetchey W. ChAdOx1 nCOV-19 vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis (CVST). BMJ Case Rep. 2021;14(6).
64. D'Agostino V, Caranci F, Negro A, Piscitelli V, Tuccillo B, Fasano F, et al. A Rare Case of Cerebral Venous Thrombosis and Disseminated Intravascular Coagulation Temporally Associated to the COVID-19 Vaccine Administration. J Pers Med. 2021;11(4).
65. Mehta PR, Apap Mangion S, Benger M, Stanton BR, Czuprynska J, Arya R, et al. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination - A report of two UK cases. Brain Behav Immun. 2021;95:514-17.
66. Al-Mayhani T, Saber S, Stubbs MJ, Losseff NA, Perry RJ, Simister RJ, et al. Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. J Neurol Neurosurg Psychiatry. 2021.
67. Blauenfeldt RA, Kristensen SR, Ernstsen SL, Kristensen CCH, Simonsen CZHvas AM. Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine. J Thromb Haemost. 2021.
68. Jones M, Boisvert A, Landry JPetrasek PF. Limb ischemia and pulmonary artery thrombosis afer the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine: a case of vaccine-induced immune thrombotic thrombocytopenia. Cmaj. 2021.
69. Haakonsen HBNystedt A. Deep vein thrombosis more than two weeks after vaccination against COVID-19. Tidsskr Nor Laegeforen. 2021;141.
70. Perry RJ, Tamborska A, Singh B, Craven B, Marigold R, Arthur-Farraj P, et al. Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. The Lancet. 2021.
71. Rzymski P, Perek BFlisiak R. Thrombotic Thrombocytopenia after COVID-19 Vaccination: In Search of the Underlying Mechanism. Vaccines (Basel). 2021;9(6).
72. Long B, Bridwell RGottlieb M. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines. Am J Emerg Med. 2021;49:58-61.
73. Sachs UJ, Cooper N, Czwalinna A, Müller J, Pötzsch B, Tiede A, et al. PF4-dependent immunoassays in patients with vaccine-induced immune thrombotic thrombocytopenia (VITT): results of an inter-laboratory comparison. Thromb Haemost. 2021.
74. Bourguignon A, Arnold DM, Warkentin TE, Smith JW, Pannu T, Shrum JM, et al. Adjunct Immune Globulin for Vaccine-Induced Thrombotic Thrombocytopenia. N Engl J Med. 2021.
75. Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. Bmj. 2021;372:n699.
76. Dyer O. Covid-19: EMA defends AstraZeneca vaccine as Germany and Canada halt rollouts. Bmj. 2021;373:n883.
77. Dyer O. Covid-19: US will send 60 million AstraZeneca doses abroad as domestic demand falls. Bmj. 2021;373:n1111.
78. Thakur KT, Tamborska A, Wood GK, McNeill E, Roh D, Akpan IJ, et al. Clinical review of cerebral venous thrombosis in the context of COVID-19 vaccinations: Evaluation, management, and scientific questions. J Neurol Sci. 2021;427:117532.
79. Mahase E. Covid-19: UK offers under 40s alternative to AstraZeneca vaccine to boost confidence. Bmj. 2021;373:n1185.
80. Mahase E. AstraZeneca vaccine: Blood clots are "extremely rare" and benefits outweigh risks, regulators conclude. Bmj. 2021;373:n931.
81. Agency EM. AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets 2021 [Available from: https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood.
82. Bae S, Lee YW, Lim SY, Lee JH, Lim JS, Lee S, et al. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea. J Korean Med Sci. 2021;36(17):e115.
83. Jeon M, Kim J, Oh CELee JY. Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System. J Korean Med Sci. 2021;36(17):e114.
84. Kim SH, Wi YM, Yun SY, Ryu JS, Shin JM, Lee EH, et al. Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience. J Korean Med Sci. 2021;36(14):e107.
85. Shin M, Hyun CY, Choi YH, Choi JY, Lee KHCho YS. COVID-19 Vaccination-Associated Lymphadenopathy on FDG PET/CT: Distinctive Features in Adenovirus-Vectored Vaccine. Clin Nucl Med. 2021.
86. Keshavarz P, Yazdanpanah F, Rafiee FMizandari M. Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review. Acad Radiol. 2021.
87. Nawwar AA, Searle J, Singh RLyburn ID. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F]Choline PET/CT-not only an FDG finding. Eur J Nucl Med Mol Imaging. 2021:1-2.
88. Allen CM, Ramsamy S, Tarr AW, Tighe PJ, Irving WL, Tanasescu R, et al. Guillain-Barré syndrome variant occurring after SARS-CoV-2 vaccination. Ann Neurol. 2021.
89. Maramattom BV, Krishnan P, Paul R, Padmanabhan S, Cherukudal Vishnu Nampoothiri S, Syed AA, et al. Guillain-Barré Syndrome following ChAdOx1-S/nCoV-19 Vaccine. Ann Neurol. 2021.
90. Román GC, Gracia F, Torres A, Palacios A, Gracia KHarris D. Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222). Front Immunol. 2021;12:653786.
91. Singh Malhotra H, Gupta P, Prabhu V, Garg RK, Dandu HAgarwal V. COVID-19 vaccination-associated myelitis. Qjm. 2021.
92. Aladdin YShirah B. New-onset refractory status epilepticus following the ChAdOx1 nCoV-19 vaccine. J Neuroimmunol. 2021;357:577629.
93. Kim JE, Lee H, Paik SS, Moon JY, Yoon HJKim SH. Delayed cutaneous reaction to ChAdOx1 nCoV-19 vaccine: Is it an 'AstraZeneca arm'? J Eur Acad Dermatol Venereol. 2021.
94. Azzi L, Toia M, Stevanello N, Maggi FForlani G. An episode of oral mucositis after the first administration of the ChAdOx1 COVID-19 vaccine. Oral Dis. 2021.
95. Soiza RL, Scicluna CThomson EC. Efficacy and safety of COVID-19 vaccines in older people. Age Ageing. 2021;50(2):279-83.
96. Organization WH. The Oxford/AstraZeneca COVID-19 vaccine: what you need to know[Available from: https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know?gclid=CjwKCAjwrPCGBhALEiwAUl9X0468Xr_yrJeCt3HCMBi1DbdoBTtAW_bWhg2OdxFnf9MifaPwkCJt_hoCUPMQAvD_BwE.
97. Hazlewood GS, Pardo Pardo J, Barnabe C, Schieir O, Barber CEH, Bernatsky S, et al. Canadian Rheumatology Association Recommendation for the Use of COVID-19 Vaccination for Patients With Autoimmune Rheumatic Diseases. J Rheumatol. 2021.
98. Allen-Philbey K, Stennett A, Begum T, Johnson AC, Dobson R, Giovannoni G, et al. Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis. Mult Scler Relat Disord. 2021;52:103028.
99. Lospinoso K, Nichols CS, Malachowski SJ, Mochel MCNutan F. A case of severe cutaneous adverse reaction following administration of the Janssen Ad26.COV2.S COVID-19 vaccine. JAAD Case Rep. 2021;13:134-37.
100. Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. 2021;384(19):1824-35.
101. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;384(23):2187-201.
102. Shay DK, Gee J, Su JR, Myers TR, Marquez P, Liu R, et al. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021. MMWR Morb Mortal Wkly Rep. 2021;70(18):680-84.
103. Tanne JH. Covid-19: US authorises Johnson and Johnson vaccine again, ending pause in rollout. Bmj. 2021;373:n1079.
104. Mahase E. Covid-19: Unusual blood clots are "very rare side effect" of Janssen vaccine, says EMA. Bmj. 2021;373:n1046.
105. Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020;383(24):2320-32.
106. Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021;384(20):1899-909.
107. Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine. 2021.
108. Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, et al. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. New England Journal of Medicine. 2021;386(6):531-43.
109. Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39-51.
110. News B. Sinopharm: Chinese Covid vaccine gets WHO emergency approval 2021 [Available from: https://www.bbc.com/news/world-asia-china-56967973.
111. Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021;326(1):35-45.
112. Almufty HB, Mohammed SA, Abdullah AMMerza MA. Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes Metab Syndr. 2021;15(5):102207.
113. Abu-Hammad O, Alduraidi H, Abu-Hammad S, Alnazzawi A, Babkair H, Abu-Hammad A, et al. Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines. Vaccines (Basel). 2021;9(6).
114. Jayadevan R, Shenoy RTs A. Survey of symptoms following COVID-19 vaccination in India. medRxiv. 2021:2021.02.08.21251366.
115. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. The Lancet Infectious diseases. 2021;21(7):939-49.
116. Chapin-Bardales J, Gee JMyers T. Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines. Jama. 2021;325(21):2201-02.
117. Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, Turner DL, et al. Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Vaccines (Basel). 2021;9(5).
118. Kunal S, Sakthivel P, Gupta NIsh P. Mix and match COVID-19 vaccines: potential benefit and perspective from India. Postgrad Med J. 2021.
119. Groß R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D, et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity. medRxiv. 2021:2021.05.30.21257971.
120. Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021.
121. Shaw RH, Stuart A, Greenland M, Liu X, Nguyen Van-Tam JSSnape MD. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021;397(10289):2043-46.
122. Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. The Lancet.
123. Hillus D, Schwarz T, Tober-Lau P, Hastor H, Thibeault C, Kasper S, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1-nCoV19 and BNT162b2: a prospective cohort study. medRxiv. 2021:2021.05.19.21257334.
124. Prevention ECfDControl. Threat assessment brief: emergence of SARS-CoV-2 B. 1.617 variants in India and situation in the EU/EEA. 2021.
125. Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of COVID-19 vaccines against the B. 1.617. 2 variant. medRxiv. 2021.
126. Li XN, Huang Y, Wang W, Jing QL, Zhang CH, Qin PZ, et al. Efficacy of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study. Emerg Microbes Infect. 2021:1-32.
127. Nanduri S, Pilishvili T, Derado G, Soe MM, Dollard P, Wu H, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1163-66.
128. Gushchin VA, Dolzhikova IV, Shchetinin AM, Odintsova AS, Siniavin AE, Nikiforova MA, et al. Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants. Vaccines (Basel). 2021;9(7).
129. Berkhout BHerrera-Carrillo E. SARS-CoV-2 Evolution: On the Sudden Appearance of the Omicron Variant. J Virol. 2022;96(7):e0009022.
130. Kumar S, Thambiraja TS, Karuppanan KSubramaniam G. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein. J Med Virol. 2022;94(4):1641-49.
131. Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet. 2022;399(10335):1618-24.
132. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. New England Journal of Medicine. 2022;386(16):1532-46.
133. Higdon MM, Baidya A, Walter KK, Patel MK, Issa H, Espié E, et al. Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant. The Lancet Infectious Diseases. 2022;22(8):1114-16.
134. Soiza RL, Scicluna CThomson EC. Efficacy and safety of COVID-19 vaccines in older people. Age and Ageing. 2021;50(2):279-83.
135. Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, et al. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. N Engl J Med. 2021;384(24):2273-82.
136. Prevention CfDCa. COVID-19 Vaccines While Pregnant or Breastfeeding 2022 [Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html#:~:text=If%20trying%20to%20get%20pregnant,testing%20before%20COVID%2D19%20vaccination.
137. Prevention CfDCa. COVID-19 Vaccine Monitoring Systems for Pregnant People 2022 [Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/monitoring-pregnant-people.html.
138. Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, et al. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut. 2021;70(5):865-75.
139. Khan NMahmud N. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications. Gastroenterology. 2021:S0016-5085(21)03066-3.
140. Xu F, Carlson SA, Wheaton AGGreenlund KJ. COVID-19 Hospitalizations Among U.S. Medicare Beneficiaries With Inflammatory Bowel Disease, April 1 to July 31, 2020. Inflammatory Bowel Diseases. 2021;27(7):1166-69.
141. Prevention CfDCa. Data and Statistics-Inflammatory Bowel Disease (IBD) in the United States 2021 [Available from: https://www.cdc.gov/ibd/data-statistics.htm.
142. Noor MTManoria P. Immune Dysfunction in Cirrhosis. Journal of clinical and translational hepatology. 2017;5(1):50-58.
143. John BV, Deng Y, Scheinberg A, Mahmud N, Taddei TH, Kaplan D, et al. Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis. JAMA Internal Medicine. 2021.
144. diseases aaftsol. COVID-19 Vaccine Recommendations for Patients with Liver Disease 2021 [Available from: https://www.aasld.org/sites/default/files/2021-04/AASLD%20COVID-19%20Vaccine%20Recommendations%20for%20Patients%20with%20Liver%20Disease%20-%20FINAL%20-%20APRIL%202021.pdf.
145. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine. 2020;383(27):2603-15.
146. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. The New England journal of medicine. 2021;384(5):403-16.
147. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. 2021;397(10275):671-81.
148. Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial. medRxiv. 2021:2021.06.30.21259439.
149. Zhu F-C, Guan X-H, Li Y-H, Huang J-Y, Jiang T, Hou L-H, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. 2020;396(10249):479-88.
150. Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. New England Journal of Medicine. 2021.
| Files | ||
| Issue | Vol 7, No 3 (2024) | |
| Section | Review Article | |
| DOI | https://doi.org/10.18502/igj.v7i3.17878 | |
| Keywords | ||
| COVID-19 SARS-CoV-2 Vaccines Safety Side Effect | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Seyedmirzaei H, Shobeiri P, Mohammadi M, Zarei M. The Safety Profile of COVID-19 Vaccines: A Narrative Review. Immunol Genet J. 2024;7(3):117-136.
